STEELE GLENN JR MD PHD
Known title: DirectorCIK: 0001269131
Associated companies
Transaction History
| PTCT | ▲ Buy | Option Exercise | 12,000 | $135K | 9/30/2026 | View on chart |
| PTCT | ▼ Sell | Open Market | 12,000 | $782K | 9/30/2026 | View on chart |
| PTCT | ▲ Buy | Option Exercise | 12,000 | $370K | 1/2/2026 | View on chart |
| PTCT | ▼ Sell | Open Market | 12,000 | $916K | 1/2/2026 | View on chart |
| PTCT | ▲ Buy | Grant | 4,000 | $0 | 1/2/2026 | View on chart |
| PTCT | ▲ Buy | Grant | 4,000 | $0 | 1/3/2025 | View on chart |
| PTCT | ▲ Buy | Grant | 4,000 | $0 | 2/15/2024 | View on chart |
| PTCT | ▲ Buy | Grant | 4,000 | $0 | 1/5/2023 | View on chart |
| PTCT | ▲ Buy | Grant | 3,200 | $0 | 1/7/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
PTC Therapeutics to Report Q3 2026 Earnings on Oct 29
PTC Therapeutics has announced it will release its third-quarter 2026 financial results on October 29, 2026. This upcoming report is the primary catalyst for the stock in the near term. The company's shares are currently trading below the average analyst price target, with the stock recently testing key support levels.
PTC Therapeutics to Report Q3 2026 Earnings on Oct 29. PTC Therapeutics has announced it will release its third-quarter 2026 financial results on October 29, 2026. This upcoming report is the primary catalyst for the stock in the near term. The company's shares are currently trading below the average analyst price target, with the stock recently testing key support levels.